StemPrintER Sciences

StemPrintER Sciences is a UK-incorporated oncology diagnostics company entity within the AccuStem group that holds the intellectual property and assets related to the StemPrintER precision oncology assay. StemPrintER is a proprietary 20-gene test designed to measure tumor “stemness” and stratify recurrence risk in patients with early-stage breast cancer, particularly ER-positive, HER2-negative disease. The business originated as a spinout from Tiziana Life Sciences in 2020 and now sits as a wholly owned subsidiary of AccuStem Sciences, which is publicly traded in the U.S. In addition to StemPrintER, the broader AccuStem platform references MSC, a 24-microRNA test intended to support lung nodule management. Overall, StemPrintER Sciences appears to function primarily as an IP-holding and operating subsidiary for AccuStem’s oncology diagnostic platform rather than as a standalone drug-development biotech.